Cancers are often caused by alterations in specific genes that result in abnormal proteins that drive cell growth and proliferation.
Some people develop cancers that are solely reliant on a cellular pathway, turned on inappropriately by a single DNA change. When a genetic test identifies a patient with a so-called “oncogenic driver,” there should be a personalized medicine to address the problem. At Loxo Oncology, we are developing a pipeline of highly selective and well-behaved drugs that inhibit oncogenic drivers in cancer.
As scientists learn more about the genetic drivers of cancer, we can find more opportunities to treat cancer, in particular by matching patients to the best therapies for their particular cancer. The increasing use of genetic testing is providing a more precise look at the underlying genetics of each cancer patient and helping to guide medical decisions and treatment.